In a report released today, Jailendra Singh from Truist Financial maintained a Buy rating on Evolent Health (EVH – Research Report). The ...

Evolent Health faces volatility with missed targets and 2024 guidance cuts. Click here for a full investment analysis of EVH ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Citizens JMP raised the firm’s price target on Evolent Health (EVH) to $13 from $12 and keeps an Outperform rating on the shares. Evolent’s Q4 ...

Full Year 2024 Results Key Financial Results Revenue: US$2.55b (up 30% from FY 2023).

Evolent Health Inc. (EVH) has disclosed a new risk, in the Technology category. Evolent Health Inc. faces significant risks associated with its ...

Welcome to the Evolent earnings conference call for the fourth quarter and year ended December 31, 2024. All participants ...

Healthcare solutions company Evolent Health (NYSE:EVH) in Q4 CY2024, but sales rose 16.3% year on year to $646.5 million.

Discover key insights from Evolent Health's Q4 2024 earnings call, focusing on 30% revenue growth, contract renegotiations, projections for 2025, ...

ARLINGTON, Va. (AP) — ARLINGTON, Va. (AP) — Evolent Health Inc. (EVH) on Thursday reported a loss of $22.8 million in its fourth quarter. The Arlington, Virginia-based company said it had a loss of 27 ...